comparemela.com

Perchek Industries Unsplash News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Post-hoc Analysis Confirms Biosimilarity Between SB15, Reference Aflibercept

The post-hoc analysis of a phase 3 clinical trial suggests SB15 has comparable clinical efficacy and safety to aflibercept in patients with nAMD.

Noord hollandSamsung bioepisMourad farouk rezkHyejin kimPerchek industries unsplashBiogen biosimilars unit

Anti-VEGF Therapy Places Time-Related Burden on Patients with nAMD

Patients with nAMD and their relatives experience a significant burden due to treatment-related time commitments, but most have no issues traveling to the eye clinic.

Erik vingePerchek industries unsplash

Faricimab Maintains Vision Improvement, Extends Intervals for RVO in Phase 3 Trials

Faricimab maintained vision improvements and extended treatment intervals up to 4 months for people with RVO in the phase 3 BALATON and COMINO trials.

United statesLevi garrawayDrug administrationPerchek industries unsplashFour monthsPeople with retinal vein occlusionPress releases

Avacincaptad Pegol Significantly Slows Geographic Atrophy Growth at 24 Months

Announced by Iveric Bio, topline results from the phase 3 GATHER2 clinical trial indicate monthly avacincaptad pegol significantly slowed GA growth compared to sham at 24 months.

United statesHcplive doctalkAvacincaptad pegolArshad khananiIveric bioDhaval desaiIapocec arshad khananiPerchek industries unsplashAmerican academy of ophthalmology annual meetingSierra eye associatesDrug administrationEuropean medicines agencyEuropean medicinesOphthalmology annual meetingBio announces positiveMonth topline results

Faricimab Effective for nAMD Eyes with Prior Anti-VEGF Treatment, Study Finds

Faricimab shows improved visual and anatomic outcomes in eyes with nAMD previously treated with aflibercept or brolucizumab.

Hidenori takahashiDrug administrationPerchek industries unsplashJichi medical universityJichi medical

vimarsana © 2020. All Rights Reserved.